ERBB2 and breast carcinoma: The results revealed that in patients with HER2 over-expressing breast cancer, a positive correlation was observed between ERCC1 expression and TIDE score (Figure 3E), suggesting that ERCC1 expression could impact the effects of immunotherapy.